INmune Bio's Expert Gambit: Building the Scaffolding for Cell Therapy's Future

BOCA RATON, FL – July 30, 2026 – In the volatile world of biotechnology, where promising science often shatters against the unforgiving realities of clinical trials and regulatory scrutiny, a company's structure is as critical as its science. This week, INmune Bio Inc. announced a move that is less about a single discovery and more about reinforcing its entire foundation. The formation of a high-powered Scientific Advisory Board (SAB) to guide its CORDStrom™ cell therapy platform is a masterclass in strategic fortification, an attempt to build the institutional scaffolding needed to carry a fragile new technology from the lab to the patient.

The announcement centers on Ebstrocel™, a therapy for the devastating rare skin disease recessive dystrophic epidermolysis bullosa (RDEB), and the broader CORDStrom™ platform from which it originates. But the real story lies in the names on the advisory roster. By assembling a team of world-renowned experts, INmune Bio is signaling a shift from speculative science to disciplined execution. This is a forensic look at how a late-stage biotech company attempts to de-risk its future and, in doing so, provides a blueprint for the maturation of the entire cell therapy sector.

Assembling the Architects of Credibility

A scientific advisory board can often be a ceremonial affair, a list of impressive names meant to add luster to a letterhead. INmune Bio’s new SAB, however, appears to be a purpose-built machine. Each member brings a specific, critical tool to the complex task of bringing a mesenchymal stromal cell (MSC) therapy to market.

The board is chaired by the company’s own Chief Scientific Officer, Professor Mark Lowdell. While an internal chair can raise questions of independence, Lowdell's deep, decades-long experience in establishing GMP-compliant cell therapy manufacturing in the UK provides a crucial link between high-level strategy and the granular reality of production. This is a working board, not a theoretical one, and his dual role ensures that the SAB’s advice is directly integrated into the company’s operational core.

The external members are a veritable who's who of the MSC world. Dr. Katarina Le Blanc from the Karolinska Institute is a pioneer who first demonstrated the clinical power of MSCs in treating graft-versus-host disease, authoring a landmark study in The Lancet. Her expertise in MSC immunobiology and regulatory affairs is essential for navigating the complex scientific and bureaucratic questions that will inevitably arise.

Dr. Anna Martinez, from London's Great Ormond Street Hospital, provides the indispensable connection to the patient. As the Clinical Lead for the UK National Epidermolysis Bullosa Service, she understands the brutal reality of RDEB and the practical challenges of delivering novel therapies to a vulnerable pediatric population. Her involvement ensures the clinical trial design and endpoints remain grounded in what is truly meaningful for patients, a factor the UK's MHRA has already emphasized.

Rounding out the team are Dr. Sowmya Viswanathan, whose work at the University of Toronto focuses on engineering potent MSC therapies for osteoarthritis—a key expansion target for the CORDStrom™ platform—and Dr. Daniel J. Weiss, the current President of the International Society for Cell & Gene Therapy (ISCT). Dr. Weiss’s leadership role in the primary global organization for the field provides an unparalleled perspective on industry-wide standards, manufacturing challenges, and regulatory trends. This isn't just about getting one drug approved; it's about building a platform that adheres to the evolving global consensus on quality and safety.

A Blueprint for a Brutal Disease

The immediate focus of this new brain trust is Ebstrocel™ and its application for RDEB. It is difficult to overstate the profound unmet need here. RDEB is a cruel genetic disorder where the skin lacks the collagen "glue" holding it together, leading to constant, painful blistering, chronic wounds, and a high risk of aggressive skin cancers. Life expectancy is short, and quality of life is abysmal. Current care is largely palliative, focused on wound management and pain control.

INmune Bio’s Phase 2 Mission EB trial for Ebstrocel has already shown promising results, with reported improvements in systemic symptoms like pain and itch. This is the scientific kernel the company is now protecting with its new strategic armor. The SAB’s task will be to translate that promise into a successful Phase 3 trial. They will advise on everything from patient selection to defining clinically meaningful endpoints that will satisfy regulators in the UK, EU, and US.

The path is daunting, but not without precedent. The recent US approval of Abeona Therapeutics' Zevaskyn for RDEB has demonstrated that regulatory bodies are willing to approve novel cell and gene therapies for this condition. However, Ebstrocel is an "off-the-shelf" allogeneic product, derived from pooled umbilical cord donors, which presents a different set of manufacturing and regulatory challenges than an autologous (patient-derived) therapy. This is precisely where the SAB's collective experience becomes invaluable—in building the robust data package required to prove that a standardized, scalable product is safe and effective.

Reinforcing the Foundations of Regenerative Medicine

Beyond the immediate goal of getting Ebstrocel to market, this move is about validating the CORDStrom™ platform itself. Historically, the broader field of MSC therapy has been plagued by inconsistency. Results have varied wildly between studies, often due to differences in cell sources, manufacturing processes, and donor variability. This lack of standardization has been a major structural weakness, hindering commercialization and eroding investor confidence.

CORDStrom™ is designed to be the solution. By using proprietary methods for screening donors, pooling cells from multiple umbilical cords, and expanding them in a controlled, cGMP-compliant process, INmune Bio aims to create a consistent, scalable, and batch-to-batch reliable product. The company has already hit critical milestones, completing commercial-scale manufacturing runs designed to meet the stringent standards of the FDA, MHRA, and EMA. This is the industrial-level infrastructure that separates a scientific concept from a viable medicine.

The SAB's mandate extends to guiding the expansion of this platform into other indications like osteoarthritis and pulmonary disease. This is where the long-term value proposition lies. If CORDStrom™ can be proven as a reliable platform technology, it can become a pipeline in a box, capable of generating multiple "tuned" cell therapies for different inflammatory and immunological diseases.

Navigating the Gauntlet of Capital and Compliance

Ultimately, scientific innovation is tethered to the unforgiving systems of finance and regulation. INmune Bio is operating on a tight timeline, with a cash runway estimated to last through the first quarter of 2027—just as it plans to be submitting its BLA to the FDA. The company is reliant on public markets to fund its ambitious plans, and investor sentiment, while cautiously optimistic, is sensitive to any perceived weakness.

In this context, the formation of the SAB is a critical move to shore up structural integrity. It sends a powerful signal to investors and potential partners that the company is mitigating risk by bringing in the best independent minds to scrutinize its strategy. It helps build a firewall of credibility around the science, making the entire enterprise a more robust structure for investment. With an aggressive regulatory timeline targeting filings in the UK, EU, and US over the next two years, proving manufacturing consistency and clinical efficacy will be paramount. The recent FDA approval of the first-ever allogeneic MSC therapy in the US provides a tailwind, but each new product must still navigate the gauntlet on its own merits. This advisory board is INmune Bio’s chosen set of navigators for that perilous journey.